|

Pemetrexed Disodium for Injection Clinical Trials

5 actively recruiting trials

▲ +1 trial since May 2026

Also known as: Pemetrexed Disodium

Pipeline

Phase 2: 1Phase 3: 3Phase 1/2: 1

Top Sponsors

  • Allist Pharmaceuticals, Inc.2
  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
  • Shanghai Hengrui Pharmaceutical Co., Ltd.1
  • Nanjing Leads Biolabs Co.,Ltd1

Indications

  • Cancer5
  • Lung Cancer2
  • Advanced Solid Tumour1
  • Recurrent Cervical Cancer1
  • NSCLC Patients With Brain Metastasis1

Other5 trials

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Phase 2
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Phase 1/2
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Phase 3
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Phase 3
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.